Insomnia treatment preferences of older adults and people living with dementia: A qualitative study
Journal of Alzheimer’s Disease · 2026
DOI: 10.1177/13872877261487350 ↗Kurz gefasst
Qualitative Studie in der Zeitschrift Journal of Alzheimer’s Disease, 2026. Verfasst von Aisling M McEvoy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Medicines Use and Safety, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Dementia, Patient Preference. Die Arbeit nennt 61 Literaturangaben.
Themen: Gerontologische Pflege, Demenz, Schlaf
Abstract (Originalsprache)
Background
Insomnia is common in people living with dementia and older adults. While clinical guidelines recommend non-pharmacological treatment as first-line therapy, insomnia is often managed with benzodiazepine receptor agonists (BZRAs), which carry a significant risk of medication-related harm.
Objective
To explore what influences decisions to engage with pharmacological and non-pharmacological insomnia treatments among older adults, people living with dementia and their carers.
Methods
Semi-structured interviews were conducted with three participant groups (people living with dementia, their carers, and older adults). The interviews were conducted and transcribed in Zoom. Participants identified and prioritized factors that influence their treatment decisions. Thematic analysis was conducted in NVivo to generate themes that described how participants’ beliefs and experiences influenced their preferences.
Results
From 19 interviews with 20 participants (Median age range = 65–74 years, 37% female), 14 factors were identified. Risk of side effects (n = 10) and effectiveness (n = 7) were most commonly prioritized and frequently reported across all participant groups. Medication side effects on cognition and daytime sedation were frequent concerns. Underpinning these factors were five main themes determined from thematic analysis, including: beliefs about sleep and insomnia, treatment expectations and experiences, external influences, treatment characteristics, and barriers to treatment.
Conclusions
Decisions about insomnia treatments are influenced not only by expected and/or experienced treatment effectiveness, but also by perceived risks and health beliefs. Integrating these perspectives into clinical decision-making may help reduce medication-related harm and promote safer, acceptable alternatives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Medicines Use and Safety, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia.
- School of Pharmacy and Biomedical Sciences, Adelaide University, Adelaide, SA, Australia.
- Health Economics Group, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
- Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.
- Faculty of Pharmacy, Laval University, Quebec, QC, Canada.
ORCID-Profile: Aisling M McEvoy, Emily Reeve, Aili V Langford, Kyung Min Kirsten Lee, Justin Turner
Zitieren
APA
McEvoy, A. M., Reeve, E., Ride, J., Langford, A. V., Lee, K. M. K., Loh, S., & Turner, J. (2026). Insomnia treatment preferences of older adults and people living with dementia: A qualitative study. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877261487350
Vancouver
McEvoy AM, Reeve E, Ride J, Langford AV, Lee KMK, Loh S, et al. Insomnia treatment preferences of older adults and people living with dementia: A qualitative study. Journal of Alzheimer’s Disease. 2026. doi:10.1177/13872877261487350
BibTeX
@article{McEvoy2026,
author = {McEvoy, Aisling M and Reeve, Emily and Ride, Jemimah and Langford, Aili V and Lee, Kyung Min Kirsten and Loh, Sheryn and Turner, Justin},
title = {Insomnia treatment preferences of older adults and people living with dementia: A qualitative study},
journal = {Journal of Alzheimer’s Disease},
year = {2026},
doi = {10.1177/13872877261487350}
}
EUVIMED